In view of the observation that UDP treatments of PBMCs were able to induce the highest expression of IFNγ (Figure 2G), a typical marker of Th1 anti-tumor response (Kanhere et al., 2012; Tibbitt et al., 2019), and to concomitantly reduce the expression of IL13 (Figure 2G), marker of Th2 immune response (Kanhere et al., 2012; Tibbitt et al., 2019), we asked whether UDP could limit the tumor growth through the stimulation of anti-tumor immune response. This evidence concerns the gene IL13 and neoplasm.